Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1350

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1350
---
 materially adversely affect our business and financial condition.

Risks
Related to Our Dependence on Third Parties

The
commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the
medical community.

Even
if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients,
healthcare payors and the medical community. The degree of market acceptance of any of our approved product candidates will depend on
a number of factors, including:

    ●
    the
    effectiveness of our approved product candidates as compared to currently available products;

    ●
    patient
    willingness to adopt our approved product candidates in place of current therapies;

    ●
    our
    ability to provide acceptable evidence of safety and efficacy;

    ●
    relative
    convenience and ease of administration;

    ●
    the
    prevalence and severity of any adverse side effects;

    ●
    restrictions
    on use in combination with other products;

    ●
    availability
    of alternative treatments;

    ●
    pricing
    and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our product
    candidates and target markets;

    ●
    effectiveness
    of our or our partners’ sales and marketing strategy;

    ●
    our
    ability to obtain sufficient third-party coverage or reimbursement; and

    ●
    potential
    product liability claims.

In
addition, the potential market opportunity for our product candidates is difficult to precisely estimate. Our estimates of the potential
market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications,
third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these assumptions
prove to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market
opportunity. If the actual market for our product candidates is smaller than we expect, our product revenues may be limited, it may be
harder than expected to raise funds, and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve
market acceptance of our product candidates in the U.S. and abroad, our revenue will be limited and it will be more difficult to achieve
profitability.

We
rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully
carry out their contractual